By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Neuraltus Pharmaceuticals, Inc. 

2483 E. Bayshore Road
Suite 212
Palo Alto  California  94303   U.S.A.
Phone: 650-424-1600 Fax: 650-320-8504



Company News
Neuraltus Pharmaceuticals, Inc. Release: Retrospective Analysis Finds Amyotrophic Lateral Sclerosis Patients With High Serum C-Reactive Protein (CRP) Levels May Respond To Immune Regulators Like NP001 4/4/2017 7:02:45 AM
Neuraltus Pharmaceuticals, Inc. Provides Enrollment Update On Confirmatory Phase II Study Of NP001 In ALS 2/9/2017 6:35:12 AM
Neuraltus Pharmaceuticals, Inc. Initiates Confirmatory Phase 2 Study Of NP001 In Patients With Amyotrophic Lateral Sclerosis 9/22/2016 6:45:37 AM
Neuraltus Pharmaceuticals, Inc. Announces Plans For Second Phase 2 Study Of NP001 In ALS Using Biomarker For Enriched Patient Selection 4/4/2016 6:55:00 AM
Biomarker Analyses Of Neuraltus Pharmaceuticals, Inc.' NP001 Phase 2 Data Demonstrate Potential For Treating ALS Patients With Systemic Inflammation 4/4/2016 6:51:38 AM
Investigator To Receive $1.5 Million Grant From The ALS Association To Help Fund Confirmatory Phase 2 Study Of Neuraltus Pharmaceuticals, Inc.' NP001 7/1/2015 6:46:07 AM
Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals, Inc.'s NP001 Potential Efficacy And Safety In ALS 4/20/2015 7:12:39 AM
Neuraltus Pharmaceuticals, Inc.' ALS Treatment Candidate, NP001, Highlighted At ALS Research Group Summit 9/17/2014 8:41:55 AM
Neuraltus Pharmaceuticals, Inc.' NP001 Phase 2 Results Highlighted At The 24th International Symposium On ALS/MND 12/9/2013 7:48:47 AM
Neuraltus Pharmaceuticals, Inc. Seeks $30 Million for New Lou Gehrig's Disease Drug Trial 10/10/2013 7:36:59 AM